

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT

NMPA APPROVAL FOR REGISTRATION OF VITAFLOW LIBERTY® FLEX

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement and product development progress of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, on December 16, 2024, VitaFlow Liberty® Flex transcatheter aortic valve implantation system (“**VitaFlow Liberty® Flex**”), our self-developed third generation transcatheter aortic valve implantation (TAVI) product received the approval from the National Medical Products Administration of the People’s Republic of China (國家藥品監督管理局) (“**NMPA**”).

VitaFlow Liberty® Flex is an upgrade to VitaFlow Liberty® delivery system, designed to work with the Group’s approved aortic valve products, which inherits all the advantages of VitaFlow Liberty® delivery system while innovatively adding 3D spatial steerable function. Its unique inner tube steering technology allows the valve to maintain coaxial alignment during the deployment, ensuring stabler and more accurate implantation, smoother and safer aortic arch passing and valve crossing. Furthermore, VitaFlow Liberty® Flex achieves commissure alignment for valve deployment, protects the coronary pathway and reserves space for future coronary interventions. This product provides physicians with excellent ease-of-use experience, further improves the efficiency and safety of surgeries, and reduces the occurrence of surgical complications. In addition, thanks to our product lifecycle management concept in the research and development stage, VitaFlow Liberty® Flex will help to lower the production cost of the Company.

The Company cannot guarantee that VitaFlow Liberty® Flex will be ultimately commercialized successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, December 17, 2024

As of the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.